These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Type 2 diabetes mellitus in youth: the complete picture to date. Gungor N; Hannon T; Libman I; Bacha F; Arslanian S Pediatr Clin North Am; 2005 Dec; 52(6):1579-609. PubMed ID: 16301084 [TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome: evaluation of pathological and therapeutic outcomes. Miranda PJ; DeFronzo RA; Califf RM; Guyton JR Am Heart J; 2005 Jan; 149(1):20-32. PubMed ID: 15660031 [No Abstract] [Full Text] [Related]
6. Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention. Sepúlveda C; Palomo I; Fuentes E Vascul Pharmacol; 2017 Apr; 91():10-17. PubMed ID: 28342822 [TBL] [Abstract][Full Text] [Related]
7. The year in atherothrombosis. Sanz J; Fuster V J Am Coll Cardiol; 2011 Aug; 58(8):779-91. PubMed ID: 21835312 [No Abstract] [Full Text] [Related]
8. Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action. Walcher D; Marx N Diab Vasc Dis Res; 2004 Oct; 1(2):76-81. PubMed ID: 16302645 [TBL] [Abstract][Full Text] [Related]
9. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J; 1998 Oct; 19(10):1434-503. PubMed ID: 9820987 [No Abstract] [Full Text] [Related]
10. Cardiovascular risk management in diabetes in primary care. Kalra S; Gupta Y J Pak Med Assoc; 2015 Aug; 65(8):907-8. PubMed ID: 26228345 [TBL] [Abstract][Full Text] [Related]
11. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Bestermann W; Houston MC; Basile J; Egan B; Ferrario CM; Lackland D; Hawkins RG; Reed J; Rogers P; Wise D; Moore MA Am J Med Sci; 2005 Jun; 329(6):292-305. PubMed ID: 15958871 [TBL] [Abstract][Full Text] [Related]
12. Strategies to reduce complications of type 2 diabetes. Ullom-Minnich P J Fam Pract; 2004 May; 53(5):366-75. PubMed ID: 15125821 [No Abstract] [Full Text] [Related]
14. [High risk pathophysiology and the molecular mechanism of arteriosclerosis]. Yamada N Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1667-75. PubMed ID: 17037299 [No Abstract] [Full Text] [Related]
15. Total risk factor management in patients with type 2 diabetes. Betteridge J Br J Hosp Med (Lond); 2005 Sep; 66(9):529-33. PubMed ID: 16200798 [No Abstract] [Full Text] [Related]
16. [Drug therapy of hyperglycemia and the prognosis of adult-onset diabetes mellitus]. Niskanen L; Uusitupa M; Laakso M Duodecim; 1999; 115(10):1122-4. PubMed ID: 11877851 [No Abstract] [Full Text] [Related]
17. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Gyberg V; De Bacquer D; De Backer G; Jennings C; Kotseva K; Mellbin L; Schnell O; Tuomilehto J; Wood D; Rydén L; Amouyel P; Bruthans J; Conde AC; Cifkova R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pająk A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D; Cardiovasc Diabetol; 2015 Oct; 14():133. PubMed ID: 26427624 [TBL] [Abstract][Full Text] [Related]